Stanford, California 94304

  • Anemia


Anemia is a common problem in the elderly. Approximately 30% of elderly patients with anemia do have an identifiable cause of the anemia. The purpose of this study is to evaluate whether intravenous iron administration in older adults with unexplained anemia could improve their clinical prognosis of anemia, cognitive and physical function, and overall quality of life. This study will constitute a randomized, controlled, open-label treatment versus wait-list/delayed intervention control group, multi-institutional pilot trial of intravenous iron sucrose in adults 65 years and older with unexplained anemia, a hemoglobin (Hb) between 9.0 g/dL and 11.5 g/dL for women and between 9.0 g/dL and 12.7 g/dL for men, and a serum ferritin between 20 and 100 ng/mL. Treatment will entail receiving IV iron either immediately (immediate intervention group) or following a wait list period of 12 weeks (wait list control group) on a weekly basis until total dose completion. IV iron sucrose will be administered during the treatment phase as weekly 200 mg infusions for 5 doses. Hypothesis: - Intravenous iron can improve mean 6 Minute Walk Test (6MWT) by at least 50 meters in adults 65 years and older with unexplained anemia and a serum ferritin between 20 and 100 ng/mL. - Intravenous iron will lead to an increase in hemoglobin (Hb) in adults 65 years and older with unexplained anemia and a serum ferritin between 20 and 100 ng/mL.


Inclusion Criteria: 1. Age >= 65 years old 2. Hb concentration >= 9.0 g/dL and < 11.5 g/dL for women and >= 9.0 to , 12.7 g/dL for men 3. Unexplained anemia 4. Serum ferritin level >= 20 and <= 100 ng/mL 5. Able to walk without the use of a walker, motorized device or the assistance of another person 6. Must be able to understand and be willing to provide written informed consent in the absence of dementia, defined as a Montreal Cognitive Assessment (MoCA) score >= 22 7. Must be able to understand and speak English Exclusion Criteria: 1. Red blood cell transfusions within the past 3 months 2. Use of erythropoiesis stimulating agents (ESA) in the past 3 months 3. Intravenous Iron Infusions within the past 3 months 4. History of unstable angina or myocardial infarction in the past 3 months 5. Distance on 6MWT above the median for age and sex adjusted population medians 6. History of stroke of transient ischemic attacks in the past 3 months 7. Uncontrolled hypertension defined as greater than the average diastolic blood pressure > 100 mm Hg or systolic blood pressure > 160 mm Hg on 2 separate occasions on 2 separate days during screening 8. Positive fecal occult blood test within the screening period 9. Elevated AST (SGOT) or ALT (SGPT) >= 2x upper limit of normal 10. Documented anaphylactic reaction to iron sucrose infusion in the past 11. Subjects initiated on oral iron supplementation within the last 6 weeks, or those initiated on oral iron within the last 3 months who have had at least a one g/dL improvement in Hb since starting oral iron supplementation



Primary Contact:

Elizabeth A Price, MD

Backup Contact:


Location Contact:

Stanford, California 94304
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.